Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lusutrombopag - Shionogi

Drug Profile

Lusutrombopag - Shionogi

Alternative Names: MULPLETA; Mulpleta; S-888711

Latest Information Update: 30 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Class Small molecules; Thiazoles
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombocytopenia
  • Discontinued Idiopathic thrombocytopenic purpura

Most Recent Events

  • 24 Jun 2019 Lusutrombopag licensed to Eddingpharm in China, Macau and Hong-Kong
  • 13 Jun 2019 Pooled adverse events data from one phase IIb and two phase III L-PLUS 1 and L-PLUS 2 trials in Thrombocytopenia presented at the 24th Congress of the European Haematology Association (EHA-2019)
  • 13 Jun 2019 Pooled efficacy data from two phase III L-PLUS 1 and L-PLUS 2 trials in Thrombocytopenia presented at the 24th Congress of the European Haematology Association (EHA-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top